From Hypertension to Hair Growth: The Unexpected Story of Minoxidil

Minoxidil is one of the most well-known treatments for hair loss today, but its origins have nothing to do with dermatology. It was first developed to treat a completely different condition: severe hypertension. Its transformation into a hair growth treatment began with an unexpected side effect. This is the story of minoxidil, from a blood pressure pill to a staple of hair regrowth.

Researchers at the Upjohn Company (now part of Pfizer) were searching for new ways to treat high blood pressure, and developed a powerful vasodilator — minoxidil — that worked by relaxing and widening blood vessels so that blood flowed more easily. In 1979 the U.S. Food and Drug Administration (FDA) approved minoxidil as an oral medication under the brand name Loniten, for patients with severe, treatment-resistant hypertension.

Doctors and patients then began reporting something unusual. Many people taking minoxidil grew excess hair — not just on the scalp, but on the arms, hands and face. This side effect, known as hypertrichosis, prompted researchers to ask whether the drug could help people with hair loss.

The Birth of a Hair Loss Treatment

Researchers began testing whether minoxidil applied directly to the scalp could promote hair growth without affecting blood pressure. Clinical trials in the 1980s supported topical minoxidil for male pattern baldness, and in 1988 the FDA approved it under the brand name Rogaine, the first medically approved treatment for androgenetic alopecia. It was initially prescription-only and available only as a 2% solution. A 5% formulation followed, and in 1996 minoxidil was approved for over-the-counter sale in the United States, which is what made it widely accessible.

Decades on, the exact mechanism is still being worked out. Reviews of the pharmacology describe several proposed actions:

Improves blood flow to the follicle: minoxidil widens blood vessels, which researchers propose allows more oxygen and nutrients to reach hair follicles.

Elongates the growth phase: the most consistently reported action is that minoxidil prolongs the anagen (growth) phase, so hairs grow for longer before shedding.

Acts on potassium channels: minoxidil is a potassium-channel opener, and this is thought to affect how follicle cells function.

May increase PGE2: some researchers propose that minoxidil raises production of prostaglandin E2, a molecule associated with the growth phase of the hair cycle.

May slow miniaturization: in pattern hair loss, follicles shrink over successive cycles until they stop producing visible hair. Minoxidil is proposed to slow this process and keep follicles active for longer.

A note on how minoxidil is activated. Minoxidil is a prodrug: in its applied form it is not fully active. Enzymes in the scalp called sulfotransferases (principally SULT1A1) convert it to its active form, minoxidil sulfate, and that is the form that acts on the follicle. People differ in how much of this enzyme activity they have. Small studies report that people with higher scalp sulfotransferase activity tend to respond better, and that lower activity is associated with a weaker response. This is a leading proposed explanation for why some people are described as minoxidil "non-responders", though it has not been confirmed in large trials, and it is the basis of ongoing research into better delivery and activation.

Expanding Use: Minoxidil for Women and Oral Treatments

Early studies of minoxidil focused on male pattern baldness. As use spread, reports emerged of benefit in women with pattern hair loss, which led to clinical research in that group. Topical 2% minoxidil was approved in the United States for women in 1991 as a prescription product, and moved to over-the-counter sale along with the men's product in 1996. Trials reported that it slowed hair loss and stimulated some growth, with the clearest results in the earlier stages of alopecia.

Later trials compared concentrations and vehicles. In a 24-week placebo-controlled trial in 404 women, once-daily 5% minoxidil foam regrew more hair than a vehicle foam (about 9 more hairs per cm²), and scalp irritation and facial hair growth were uncommon in both groups (Bergfeld et al. 2016). The FDA approved once-daily 5% foam for women in 2014.

Low-dose oral minoxidil (LDOM) has more recently become a widely discussed option for people who do not respond well to, or cannot tolerate, the topical form. It is a prescription medicine used off-label for hair loss, at doses far below the antihypertensive range, and dermatologists who use it report that it bypasses the scalp-absorption problem by acting systemically. It also carries risks the topical form does not, including fluid retention, effects on heart rate and blood pressure, and hair growth in unwanted places (hypertrichosis). The tablet's US label carries a boxed warning that minoxidil can cause pericardial effusion (fluid around the heart), occasionally progressing to tamponade, and can worsen angina; for blood pressure it is given with a beta-blocker and usually a diuretic (DailyMed, minoxidil tablets). Those warnings were written for high antihypertensive doses; how they apply at hair-loss doses has not been established in controlled trials. Dose selection and monitoring are decisions for a prescribing doctor, not something to self-manage.

Topical minoxidil is sold over the counter in many countries, typically at 2% and 5%. Access varies: regulation differs between countries, formulations include liquid, foam and (by prescription) oral tablets, and both brand-name and generic versions exist at different prices. Online pharmacies have widened availability, but rules on higher concentrations and on oral prescriptions vary by country.

Research and Studies on Minoxidil

Minoxidil has been studied continuously since its dermatological use began. The first clinical trials in the 1980s supported its effectiveness in men with androgenetic alopecia and led to the 1988 FDA approval.

On concentration, a randomized clinical trial by Olsen and colleagues, published in the Journal of the American Academy of Dermatology in 2002, compared 5% topical minoxidil with 2% topical minoxidil and placebo in men with androgenetic alopecia, and reported greater hair growth with the 5% solution. That trial is frequently mis-cited as evidence for women; it was conducted in men.

A 2012 review by Rossi and colleagues in Recent Patents on Inflammation & Allergy Drug Discovery surveys minoxidil's dermatological uses and its side-effect profile, and remains a standard reference for the pharmacology.

On delivery methods, a randomized evaluator-blinded pilot study by Dhurat and Sukesh, published in the International Journal of Trichology in 2013, compared microneedling combined with 5% minoxidil against 5% minoxidil alone in men with androgenetic alopecia, and reported greater hair counts in the microneedling group. A 2020 literature review co-authored by Fabbrocini in Dermatologic Therapy summarizes the microneedling literature and concludes that the evidence, while encouraging, comes largely from small studies.

On combination with tretinoin, a randomized, double-blind trial by Shin and colleagues in American Journal of Clinical Dermatology (2007) compared 5% minoxidil applied twice daily with a combined 5% minoxidil plus 0.01% tretinoin solution applied once daily in 31 men. The authors found no statistically significant difference between the two regimens and described them as equivalent, but a trial of 31 men is too small to show that two treatments work equally well or are equally safe. At most, it suggests once-daily application with tretinoin may be an option, not a way to get a larger effect. Tretinoin is a prescription retinoid that increases how much minoxidil is absorbed through the skin, and combining them is an off-label decision for a prescriber, not a home formulation exercise.

Antiandrogen approaches are also studied alongside minoxidil. Finasteride and dutasteride are 5-alpha-reductase inhibitors: they reduce the amount of dihydrotestosterone (DHT) the body produces, rather than blocking DHT at its receptor. Both are prescription medicines with their own risk profiles and are used in combination with minoxidil only under medical supervision.

For female pattern hair loss specifically, the clinical and pathophysiological review by Ramos and Miot in Anais Brasileiros de Dermatologia (2015) and the treatment overview by Tosti and Duque-Estrada in Expert Opinion on Pharmacotherapy (2009) are useful summaries of where minoxidil sits among the options.

The Future of Minoxidil: What's Next?

More than 40 years after its first approval, minoxidil remains one of the most widely used and most studied treatments for hair loss. Current research is aimed at improving efficacy, reducing side effects, and making application more convenient.

One line of work is matching the treatment to the individual's scalp enzyme activity. Because minoxidil has to be converted to minoxidil sulfate by SULT1A1, researchers have investigated whether a test of that enzyme activity could predict who is likely to respond, which would open the door to more individualized treatment. This work is still at the research stage; no such test is part of routine care.

A second line is improved delivery. Nanoencapsulation and lipid nanoparticle formulations are being investigated as ways to release the drug in a more controlled way, reduce evaporation of the vehicle used in conventional solutions, and potentially cut the number of applications needed. These are laboratory and early-stage formulations, not products in general use.

A third is microneedling, which reviews propose may increase minoxidil's penetration into the scalp; the trials measured hair counts, not how much minoxidil entered the skin. The published studies are mostly small, and reviewers note that technique, needle depth and session frequency are not standardized.

Minoxidil in Combination with Other Treatments

Combination therapy has been widely investigated. As above, tretinoin increases minoxidil absorption, and the small Shin 2007 trial (31 men) found no significant difference between once-daily combined application and twice-daily minoxidil alone; it was too small to show the two are equivalent. 5-alpha-reductase inhibitors, which reduce DHT production, are sometimes prescribed alongside minoxidil: finasteride 1 mg is approved for hair loss in men, while dutasteride is not approved for hair loss in the US or EU (it is approved for male pattern hair loss in South Korea and Japan). Both have label warnings, including sexual side effects that may continue after stopping, and women who are or may be pregnant should not handle the tablets or capsules.

Researchers have also examined anti-inflammatory agents intended to reduce the scalp irritation that some people get from minoxidil, including work on flavonoids and antioxidants. This is exploratory: it has not produced an established combination product, and none of it should be read as a recommendation to layer additional actives onto a scalp treatment.

Experiences and Community Discussion: How Do People Respond to Minoxidil?

Minoxidil use remains a widely discussed topic in online forums and communities, where people share their experience with different formulations and doses. One recurring theme is concern about dependence on the treatment: community users ask whether follicles treated with minoxidil come to depend on it for continued growth. Some report that after stopping, treated hair quickly re-miniaturizes; others describe a more gradual loss.

Another common discussion is variation between brands and formulations. There have been recurring community debates about whether particular batches of low-cost minoxidil have reduced efficacy, with users linking it to packaging or formulation changes. Others compare liquid and foam versions, weighing absorption against scalp irritation.

Community users also discuss low-dose oral minoxidil, with testimonials about both effectiveness and adverse effects. Some report noticeable hair growth without the irritation of the topical form; others report fluid retention or hair growth in unwanted areas. These are personal accounts, not trial data, and oral minoxidil is a prescription medicine.

These discussions reflect how variable the response to minoxidil is, and why individual factors — scalp enzyme activity, tolerance, and the type and stage of hair loss — matter when choosing a treatment strategy.

Talk to a doctor, dermatologist or pharmacist before starting, stopping or combining minoxidil — particularly before using the oral form, which is prescription-only and used off-label for hair loss, and before adding tretinoin, finasteride or dutasteride. People with heart or blood-pressure conditions, and anyone who is pregnant or breastfeeding, should get medical advice before using minoxidil in any form.

Sources

Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 47(3), 377-385. PMID 12196747. https://pubmed.ncbi.nlm.nih.gov/12196747/

Rossi, A., Cantisani, C., Melis, L., Iorio, A., & Scali, E. (2012). Minoxidil use in dermatology, side effects and recent patents. Recent Patents on Inflammation & Allergy Drug Discovery, 6(2), 130-136. PMID 22409453. https://pubmed.ncbi.nlm.nih.gov/22409453/

Dhurat, R., Sukesh, M., Avhad, G., Dandale, A., & Pal, A. (2013). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. International Journal of Trichology, 5(1), 6-11. PMID 23960389. https://pubmed.ncbi.nlm.nih.gov/23960389/

Shin, H. S., Won, C. H., Lee, S. H., Kwon, O. S., & Kim, K. H. (2007). Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. American Journal of Clinical Dermatology, 8(5), 285-290. PMID 17902730. https://pubmed.ncbi.nlm.nih.gov/17902730/

Ocampo-Garza, S. S., Fabbrocini, G., Ocampo-Candiani, J., Cinelli, E., & Villani, A. (2020). Micro needling: a novel therapeutic approach for androgenetic alopecia, a review of literature. Dermatologic Therapy, 33(6), e14267. PMID 32882083. https://pubmed.ncbi.nlm.nih.gov/32882083/

Ramos, P. M., & Miot, H. A. (2015). Female pattern hair loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia, 90(4), 529-543. PMID 26375223. https://pubmed.ncbi.nlm.nih.gov/26375223/

Tosti, A., & Duque-Estrada, B. (2009). Treatment strategies for alopecia. Expert Opinion on Pharmacotherapy, 10(6), 1017-1026. PMID 19364249. https://pubmed.ncbi.nlm.nih.gov/19364249/

Bergfeld, W., Washenik, K., Callender, V., et al. (2016). A Phase III, multicenter, parallel-design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss. Journal of Drugs in Dermatology, 15(7), 874-881. PMID 27391639. https://pubmed.ncbi.nlm.nih.gov/27391639/

Minoxidil tablets, USP — prescribing information (boxed warning). DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b4fc036-9497-442b-b629-c4b386932789